Cargando…

A novel neurodegenerative spectrum disorder in patients with MLKL deficiency

Mixed lineage kinase domain-like (MLKL) is the main executor of necroptosis, an inflammatory form of programmed cell death. Necroptosis is implicated in combating infections, but also in contributing to numerous other clinical conditions, including cardiovascular diseases and neurodegenerative disor...

Descripción completa

Detalles Bibliográficos
Autores principales: Faergeman, Soren L., Evans, Hayley, Attfield, Kathrine E., Desel, Christiane, Kuttikkatte, Subita Balaram, Sommerlund, Mette, Jensen, Lise Torp, Frokiaer, Jorgen, Friese, Manuel A., Matthews, Paul M., Luchtenborg, Christian, Brügger, Britta, Oturai, Annette Bang, Dendrou, Calliope A., Fugger, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195448/
https://www.ncbi.nlm.nih.gov/pubmed/32358523
http://dx.doi.org/10.1038/s41419-020-2494-0
_version_ 1783528536801280000
author Faergeman, Soren L.
Evans, Hayley
Attfield, Kathrine E.
Desel, Christiane
Kuttikkatte, Subita Balaram
Sommerlund, Mette
Jensen, Lise Torp
Frokiaer, Jorgen
Friese, Manuel A.
Matthews, Paul M.
Luchtenborg, Christian
Brügger, Britta
Oturai, Annette Bang
Dendrou, Calliope A.
Fugger, Lars
author_facet Faergeman, Soren L.
Evans, Hayley
Attfield, Kathrine E.
Desel, Christiane
Kuttikkatte, Subita Balaram
Sommerlund, Mette
Jensen, Lise Torp
Frokiaer, Jorgen
Friese, Manuel A.
Matthews, Paul M.
Luchtenborg, Christian
Brügger, Britta
Oturai, Annette Bang
Dendrou, Calliope A.
Fugger, Lars
author_sort Faergeman, Soren L.
collection PubMed
description Mixed lineage kinase domain-like (MLKL) is the main executor of necroptosis, an inflammatory form of programmed cell death. Necroptosis is implicated in combating infections, but also in contributing to numerous other clinical conditions, including cardiovascular diseases and neurodegenerative disorders. Inhibition of necroptosis is therefore of therapeutic interest. Here we report two siblings both of whom over the course of 35 years developed a similar progressive, neurodegenerative spectrum disorder characterized by paresis, ataxia and dysarthria. Magnetic resonance imaging of their central nervous system (CNS) revealed severe global cerebral volume loss and atrophy of the cerebellum and brainstem. These brothers are homozygous for a rare haplotype identified by whole genome sequencing carrying a frameshift variant in MLKL, as well as an in-frame deletion of one amino acid in the adjacent fatty acid 2-hydroxylase (FA2H) gene. Functional studies of patient-derived primary cells demonstrated that the variant in MLKL leads to a deficiency of MLKL protein resulting in impairment of necroptosis. Conversely, shotgun lipidomic analysis of the variant in FA2H shows no impact on either the abundance or the enzymatic activity of the encoded hydroxylase. To our knowledge, this is the first report of complete necroptosis deficiency in humans. The findings may suggest that impaired necroptosis is a novel mechanism of neurodegeneration, promoting a disorder that shares some clinical features with primary progressive multiple sclerosis (PPMS) and other neurodegenerative diseases. Importantly, the necroptotic deficiency does not cause symptoms outside the nervous system, nor does it confer susceptibility to infections. Given the current interest in pharmacological inhibition of necroptosis by targeting MLKL and its associated pathways, this strategy should be developed with caution, with careful consideration of the possible development of adverse neurological effects.
format Online
Article
Text
id pubmed-7195448
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71954482020-05-05 A novel neurodegenerative spectrum disorder in patients with MLKL deficiency Faergeman, Soren L. Evans, Hayley Attfield, Kathrine E. Desel, Christiane Kuttikkatte, Subita Balaram Sommerlund, Mette Jensen, Lise Torp Frokiaer, Jorgen Friese, Manuel A. Matthews, Paul M. Luchtenborg, Christian Brügger, Britta Oturai, Annette Bang Dendrou, Calliope A. Fugger, Lars Cell Death Dis Article Mixed lineage kinase domain-like (MLKL) is the main executor of necroptosis, an inflammatory form of programmed cell death. Necroptosis is implicated in combating infections, but also in contributing to numerous other clinical conditions, including cardiovascular diseases and neurodegenerative disorders. Inhibition of necroptosis is therefore of therapeutic interest. Here we report two siblings both of whom over the course of 35 years developed a similar progressive, neurodegenerative spectrum disorder characterized by paresis, ataxia and dysarthria. Magnetic resonance imaging of their central nervous system (CNS) revealed severe global cerebral volume loss and atrophy of the cerebellum and brainstem. These brothers are homozygous for a rare haplotype identified by whole genome sequencing carrying a frameshift variant in MLKL, as well as an in-frame deletion of one amino acid in the adjacent fatty acid 2-hydroxylase (FA2H) gene. Functional studies of patient-derived primary cells demonstrated that the variant in MLKL leads to a deficiency of MLKL protein resulting in impairment of necroptosis. Conversely, shotgun lipidomic analysis of the variant in FA2H shows no impact on either the abundance or the enzymatic activity of the encoded hydroxylase. To our knowledge, this is the first report of complete necroptosis deficiency in humans. The findings may suggest that impaired necroptosis is a novel mechanism of neurodegeneration, promoting a disorder that shares some clinical features with primary progressive multiple sclerosis (PPMS) and other neurodegenerative diseases. Importantly, the necroptotic deficiency does not cause symptoms outside the nervous system, nor does it confer susceptibility to infections. Given the current interest in pharmacological inhibition of necroptosis by targeting MLKL and its associated pathways, this strategy should be developed with caution, with careful consideration of the possible development of adverse neurological effects. Nature Publishing Group UK 2020-05-01 /pmc/articles/PMC7195448/ /pubmed/32358523 http://dx.doi.org/10.1038/s41419-020-2494-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Faergeman, Soren L.
Evans, Hayley
Attfield, Kathrine E.
Desel, Christiane
Kuttikkatte, Subita Balaram
Sommerlund, Mette
Jensen, Lise Torp
Frokiaer, Jorgen
Friese, Manuel A.
Matthews, Paul M.
Luchtenborg, Christian
Brügger, Britta
Oturai, Annette Bang
Dendrou, Calliope A.
Fugger, Lars
A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title_full A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title_fullStr A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title_full_unstemmed A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title_short A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
title_sort novel neurodegenerative spectrum disorder in patients with mlkl deficiency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195448/
https://www.ncbi.nlm.nih.gov/pubmed/32358523
http://dx.doi.org/10.1038/s41419-020-2494-0
work_keys_str_mv AT faergemansorenl anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT evanshayley anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT attfieldkathrinee anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT deselchristiane anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT kuttikkattesubitabalaram anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT sommerlundmette anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT jensenlisetorp anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT frokiaerjorgen anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT friesemanuela anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT matthewspaulm anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT luchtenborgchristian anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT bruggerbritta anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT oturaiannettebang anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT dendroucalliopea anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT fuggerlars anovelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT faergemansorenl novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT evanshayley novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT attfieldkathrinee novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT deselchristiane novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT kuttikkattesubitabalaram novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT sommerlundmette novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT jensenlisetorp novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT frokiaerjorgen novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT friesemanuela novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT matthewspaulm novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT luchtenborgchristian novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT bruggerbritta novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT oturaiannettebang novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT dendroucalliopea novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency
AT fuggerlars novelneurodegenerativespectrumdisorderinpatientswithmlkldeficiency